Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

Similar documents
Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

(3) Educational Activities or Lectures for this Company Generates Revenue for Duke $5K $25K >$25K

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

Method of Declaration. Hospitality/Interest/Sponsorship

Ownership/ Partnership/ Principal. None None None Lantheus Medical Imaging (DSMB) NIH (DSMB)* None None None None None None

GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS

Appendix 1. Participants in the ACCF/AHA Consensus Conference on Professionalism and Ethics

Previous Attendees List:

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION)

Associate Director. Biomarker Operations Lead. Business Development & Strategic Alliances. Business Development Executive

TRENDS IN IP DISPUTES

ACC.13 Committee Disclosures Page 1 of 9

Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D

Early Valuation. Company Portfolio

Monetizing Early-Stage R&D Assets. March 18, 2015

2017 IPCC Attendee List

HESI Annual Meeting January 19, Welcome!!!! Meeting of the. HESI Assembly of Members. Dr. James MacDonald President of HESI 01/19/09

2018 Building Better Business Connections (3BC) Event Optimizing the Role of Male Champions

Committee Disclosures Page 1 of 12

The 2011 EU industrial R&D investment SCOREBOARD

ACC.17 Program Committee Disclosures of Relationships With Industry Disclosures

European companies outpace American counterparts in R&D investment growth for the first time in five years

Healthcare and Life Sciences Group MERGERS & ACQUISITIONS

Healthcare and Life Sciences Group MERGERS & ACQUISITIONS

Innovation and the Changing Practice of Medicine

Healthcare and Life Sciences Group MERGERS & ACQUISITIONS

Healthcare and Life Sciences Group MERGERS & ACQUISITIONS

SZF Associates. SZF is an issues-oriented, evidence-based market research and consulting firm serving the pharmaceutical and biotech industry.

Healthcare and Life Sciences Group. Mergers & Acquisitions

Committee Member Employment Consultant Speaker s Bureau Ownership/ Partnership / Principal. Expert Witness

Healthcare and Life Sciences Group MERGERS & ACQUISITIONS

30th Annual Oncology Nurses Symposium

Healthcare and Life Sciences Group MERGERS & ACQUISITIONS

State of Licensing 2011 Update

Johnson & Johnson (JNJ) - Medical Equipment - Deals and Alliances Profile

Other appointments: Chairman of the Advisory Committee of Zentiva Group, Industrial Advisor EQT.

Peter Forman President & CEO South Shore Chamber of Commerce

Life Sciences CONFERENCE SERIES. Business Information in a Global Context LIFE SCIENCES IP PORTFOLIO. Business Development Pack

Cardiac Safety Research Consortium: A Decade of CSRC. Mitchell W. Krucoff, MD, FACC

IP for Development Indian Approach

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through

The 2010 EU industrial R&D investment SCOREBOARD

Corporate Compliance & Transparency

LIGHTHOUSE. The Science of Pharmaceutical Manufacturing

HEARTS/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNMMI 2014 Health Policy Statement on Use of Noninvasive Cardiovascular Imaging

2018 IPCC Attendee List

Born Ph.D. from Karolinska Institutet in Stockholm. Board member since 2016.

Eric J. Marandett. Practice Group Leader PRACTICE FOCUS. T +1 (617)

MedAdNews. themagazineofpharmaceuticalbusinessandmarketing medadnews.com october2007. What leaders need

International Strategy Development Training: a personal strategic development workshop for Life Sciences Executives of SMEs

Institutional, Organizational, or Other Financial. Ownership/ Partnership/Principa. Speakers Bureau. Reviewer Representation Employment Consultant

2018 Annual Liver Meeting November 9-13, 2018 San Francisco, CA

MARKUSH FOR PATENT ANALYSIS. Steve Hajkowski ChemAxon UGM Budapest 2013

Management Team. Bruce C. Cozadd Chairman and Chief Executive Officer

Launch of new transatlantic specialty pharma company

Baxter 2007 Investor Conference March 14, 2007

SPONSORSHIP 2009 guide

CAN Company Name M Company A A A A O N Corporation A T & T Corp Abbvie Corp Accenture Ltd.

ACC.18 ABSTRACT REVIEWERS Disclosures

SPONSORSHIP OPPORTUNITIES. Engage With Policymakers Connect With Biomedical Leaders Increase Your Corporate Visibility

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

Researched Medicines Industry Association of New Zealand Incorporated

The importance of transnational corporations in research and development activities in the world

MATCHING GIFT COMPANY LIST

VALUE IN HEALTH 20 (2017) A384 A397

Gilead Sciences. Very interesting in all areas. COMPANY Gilead Sciences Inc. INDUSTRY Biotechnology TYPE Public Company TICKER NasdaqGS:GILD

7th Annual Oncology Update A CME review of the 2010 ASCO Annual Meeting June August Exhibitor Prospectus. About the Course

Heart Valve Summit: Medical, Surgical and Interventional Decision Making

Officer Director etc. Ownership Partnership Principal. Speaker's Bureau

SPC developments in Europe AIPPI Marjan Noor Simmons & Simmons

Perspectives on Sustainable Growth

Disclosures of Relevant Financial Relationships

on the Anne Berberi, formerly Product Manager, Diabetes, at Bristol-Myers Squibb, has been appointed Senior Brand Manager, HCV, at AbbVie.

Women leaders transforming the future through gender partnership

William E. Solander. Case Highlight

Case BLS Doc 258 Filed 01/31/19 Page 1 of 2 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE

UBS Pathfinders Trust, Treasury and Growth Stock Series 23

This report is prepared by:

9455 TOWNE CENTRE DRIVE CLASS-A LIFE SCIENCE + OFFICE

Scientists Without Borders

Reference List Cha, Myoung., and Theresa Lorriman. February Why Pharma megamergers work. McKinsey&Company Our insights. Ward, Andrew.

March 20, The Honorable Dianne Feinstein United State Senate 331 Hart Office Building Washington, DC Dear Senator Feinstein:

IPCAA. Regulatory awareness still needs improving. INTERNATIONAL PHARMACEUTICAL CONGRESS ADVISORY ASSOCIATION No. 35 July 2010

1. Your Identity. Photo. Treasurer. Application for the following position in the EHRA Board: Title: Prof, MD. Family Name(s): Pürerfellner

People. Move. on the. Pierre Benjamin, MD, has been appointed Project Leader, Zavesca, at Actelion Pharmaceuticals.

Form FI. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007.

Say on Pay at the Life Sciences 80 A Final Look at 2015 Before we turn our full attention to the

VentureSource Europe -- 3Q 2014

LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter)

SPONSORSHIP OPPORTUNITIES ADVANCING CALIFORNIA BIOMEDICAL RESEARCH AND INNOVATION *BRAND RECOGNITION * MARKETING OPPORTUNITIES * NETWORKING * ACCESS*

Partnering and Product Development A Case Study of Inspiration Biopharmaceuticals, Inc.

Skystar Bio-Pharmaceutical Co SKBI

PROTECT Project. Joanna Groves Chief Executive Officer 27 April 2010 EFPIA Patient Think-Tank Brussels, Belgium

Sanofi Announces Changes to Executive Committee Aligned to its Strategic Roadmap 2020

vision without limits BIOTECH CANTY PROCESS TECHNOLOGY BUFFALO DUBLIN THAILAND

Transcription:

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Year(s): Jan 2015 to December 2015 Name: Adam DeVore Title: Instructor in Medicine Address: 2400 Pratt Street, Durham, NC 27705 Please complete the applicable rows in the following table. Monetary amounts are on an annual basis. Lectures for CME) for >$5K/1% Abbott Laboratories Abiomed Achillion Air Products, PLC Alcon Aldagen, Alexion Allergan, Alnylam Altarum Alpharma, Amerigroup Corp. Amgen, Amylin, Anadys Anesiva, page 1 of 12; 10/01/2012

Lectures for CME) for >$5K/1% Angel Medical Systems, Aptus Endosystems, ArgiNox Array Biopharma Astellas Pharma US Astra Hassle AstraZeneca Atritech Aventis Baxter Bayer US (Bayer AG/Bayer in Japan subsidiaries) Bayer HealthCare (formerly Berlex Labs) Bayer (JP) Bayer Yakuhin, Ltd. BG Medicine BioCryst Biogen Idec Bioheart 2 of 12;10/01/2010

Lectures for CME) for >$5K/1% Biomarker Factory Boehringer Ingelheim Boehringer Manheim Boston Scientific Bristol Myers Squibb Canyon Cappella Cardinal CardioDx, Cardioxyl Celsion Centocor Ceremed, Cerexa, Charles River Laboratories Chase Medical Cochrane Conatus, Conor Medsystems, Cordis 3 of 12;10/01/2010

Lectures for CME) for >$5K/1% Covidien Critical Diagnostics CSL Limited Cubist CV Therapeutics, Cytokinetics, Daiichi Sankyo Dendreon DURECT Edwards Lifesciences Elesvier Eli Lilly & EnteroMedics, EOCI Pharmacomm Ltd. Ethicon Endo- Surgery Ethicon, Evalve, Exoxemis F2G, Ltd. Genentech 4 of 12;10/01/2010

Lectures for CME) for >$5K/1% General Electric Healthcare Genomic Health Genzyme Gilead Sciences, Glaxo SmithKline (GSK) GlobeImmune Gloucester GlycoMimetics, Guidant Heartscape Technologies, Helsinn Healthcare Hoffmann-La Roche Hospira, Human Genome Sciences, ico Therapeutics Idera, Ikaria INC Inimex 5 of 12;10/01/2010

Lectures for CME) for >$5K/1% Innocoll Inspire Intarcia Therapeutics, Ischemix, Iverson Genetic Diagnostics, Janssen Products Johnson & Johnson Johnson & Johnson & Development KAI Kaiser Permanente Life Masters Supported Self Care, Lilly Luitpold, M-3 Information 6 of 12;10/01/2010

Lectures for CME) for >$5K/1% MAQUET Cardiovascular LLC (formerly Boston Scientific Cardiac & Vascular) MedImmune Medscape, LLC Medtronic Diabetes Medtronic Vascular, (formerly Medtronic AVE) Medtronic, Merck & Co. Merck Group Merck Sharp & Dohme I.A. Millennium, (formerly COR Therapeutics) Miracor Medical Systems Momenta NeoPharm, Neuron 7 of 12;10/01/2010

Lectures for CME) for >$5K/1% NeuroScience, NovaCardia, Novartis AG Group Novartis Novartis Vaccines and Diagnostics, (formerly Chiron Corp) Oncura OrbusNeich Orexigen Therapeutics, Ortho-McNeil- Janssen, Ortho-McNeil- Janssen Scientific Affairs, L.L.C. OSI Eyetech OSI Osiris Therapeutics, Otsuka America Palo Alto CSCC 8 of 12;10/01/2010

Lectures for CME) for >$5K/1% PENTAX Medical Peregrine Pfizer Pharmacyclics Pharmassest, Pharmos Phyxius Pharms LLC Pluristem Therapeutics, Portola POZEN Proctor & Gamble ProStrakan, Proventys Regado Biosciences, Revalesio Corp Roche Diagnostic Corp. Roche Group Roche Molecular Systems, RTI Health Solutions Sanofi-Aventis 9 of 12;10/01/2010

Lectures for CME) for >$5K/1% Sanofi Pasteur, (formerly Aventis Pasteur) Santaris Pharma A/S Schering-Plough Scios, SCYNEXIS Shire PLC Siemens Solvay, SRI International Summit Sunovion, Takeda Co. Tengion Tethys Bioscience The EMMES The Medicines Theravance Theregen, 10 of 12;10/01/2010

Lectures for CME) for >$5K/1% Three Rivers Transition, UCB Pharma United Therapeutics United Healthcare Veridex Vertex, Viacor, Inc Westat Wyeth XTL Biopharmaceuticals ZymoGenetics, Thoratec American Heart Association Column Explanations: (1) Funding is provided for my effort in research grants or contracts for multi-center projects in which I serve as either the Chairman, Co-Chairman, Executive or Steering Committee member or I am involved as a DCRI faculty leader for specific aspects in a project. A check in this column denotes that I am involved in such a research contract. Payments for the work performed for these contracts are made to the. A portion of my salary as a faculty member, representative of % effort on the project, is supported by these funds. 11 of 12;10/01/2010

research grant company supports the expenses associated with projects in the DUHS that are under my direction. (3) I provide educational activities or deliver occasional lectures that generate revenue company. All revenues from these activities are paid to the. None of it is taken for personal income. The three columns represent annual payments of more than $5,000, between $5,000 and $25,000, and in excess of $25,000 per year company. (4) I receive personal income outside of my salary for consulting or other services (Including CME) company. The three columns represent annual payments of more than $5,000, between $5,000 and $25,000, and in excess of $25,000 per year company. (5) I receive personal income outside of my salary for consulting or other non-cme services company. The three columns represent annual payments of more than $5,000, between $5,000 and $25,000, and in excess of $25,000 per year company. personally receive royalties in excess of $5,000 per year company. (7) I, or an immediate member of my family, have equity (with shareholder voting privileges) in this company of either > $5,000 or > 1%. 12 of 12;10/01/2010